AIM ImmunoTech Inc. — 2015 Q1 Form 10-Q Summary
Filing identity: The supplied filing is Hemispherx Biopharma, Inc.’s Form 10-Q for the quarter ended March 31, 2015; it does not identify the registrant as AIM ImmunoTech. Financial figures below are in U.S. dollars, generally thousands, unless stated otherwise.
Business context and reporting period
Hemispherx was a specialty pharmaceutical company focused on developing immune-based therapies. Its lead products were experimental Ampligen and Alferon N Injection, which was approved for a limited genital-wart indication but had no commercial finished-goods inventory available for sale. The company also described experimental Alferon LDO and research collaborations, including Ebola-related work.
Financial performance and position
| Metric | Q1 2015 | Q1 2014 / prior period |
|---|---|---|
| Revenue | $36 | $76 |
| Operating loss | $(4,923) | $(5,112) |
| Net loss | $(3,445) | $(3,836) |
| Net loss per share | $(0.02) | $(0.02) |
| Cash used in operating activities | $(4,257) | $(2,895) |
- Research and development expense was $2,674, up 15%; general and administrative expense was $1,913, down 25%; production costs were $372, up 15%.
- The quarter’s $1,374 gain from selling New Jersey net operating losses contributed materially to the lower net loss. Interest and other income was $106.
- At March 31, cash and cash equivalents were $2,942 and marketable securities were $14,063, totaling $17,005. Current assets were $17,917 versus current liabilities of $3,821. Total assets were $30,791 and stockholders’ equity was $26,970.
- Reported liabilities were principally current: accounts payable of $2,317, accrued expenses of $1,489, and a $15 current capital-lease balance. The filing reports no long-term debt balance on the presented balance sheet.
- Operating cash use was partly offset by $5,242 of net proceeds from an at-the-market share offering. The company issued 21,732,904 shares during the quarter; shares outstanding were 225,737,722 at quarter-end.
Material changes versus the prior comparable period
- Net loss narrowed by $391, or about 10%, mainly because general and administrative expense fell by $626 and the NOL-sale gain increased by $248. Higher R&D and production costs and lower investment income partly offset these improvements.
- Revenue fell by $40, or 53%, as lower prescribed Ampligen dosages outweighed a slight increase in patients using the cost-recovery program. Revenue came from the open-label Ampligen program; there were no commercial Alferon sales.
- Operating cash use increased by $1,362. Management attributed the increase mainly to payment of approximately $1,232 in 2014 executive incentive bonuses and a $480 inventory build.
- Property and equipment, net, increased to $11,805 from $4,601 as completed New Brunswick facility construction was placed in service; construction in progress fell from $7,337 to zero.
Outlook, management commentary, risks, contingencies, and unusual items
- Funding and liquidity: Management warned that additional financing may be needed if product commercialization does not occur. It said costs of the additional work sought by the FDA for Ampligen were beyond current financial resources. Further equity financing could dilute shareholders; management also noted restrictions affecting the use of some authorized shares for fundraising.
- Ampligen: The FDA’s February 2013 Complete Response Letter declined to approve the CFS application and called for at least one additional clinical trial, nonclinical studies, data analyses, and manufacturing-process work. Management estimated a new trial could take about 18 months to three years after acceptance of its design, but had not established its scope, cost, or timing. Ampligen Ebola findings cited in the filing were laboratory and animal results, not evidence of human efficacy; further studies would be needed.
- Alferon manufacturing: Production validation and new API production had begun, but commercial sales depended on an FDA pre-approval inspection and FDA release of finished product after satisfactory quality and stability data. Management anticipated commercial approval no earlier than the second half of 2015 and said emergency-use product might possibly be available in the first half. These were expectations, not assurances.
- Other development: The Alferon LDO Phase II influenza study remained delayed. The company reported a March 2015 exclusive agreement with Emerge Health to seek Ampligen approval and distribute it on a named-patient basis in Australia and New Zealand.
- Legal matters: Several shareholder and employment-related cases remained unresolved. A securities class-action settlement was subject to court approval; the court preliminarily approved it on April 8, 2015, after quarter-end, with a final approval hearing scheduled for July 22, 2015. The company reported no loss contingency accrual for the matters described and said their outcomes were uncertain.
- Other items: The company reported an accumulated deficit of $281,214 and stated it had not reported a net profit since 1987. Its statements caution that interim results are not necessarily indicative of full-year results. Management concluded disclosure controls were effective as of March 31, 2015.
Most important facts for investors to verify
- Confirm the issuer’s identity and corporate-name history: this source is a Hemispherx Biopharma 10-Q, although the request metadata names AIM ImmunoTech.
- Check subsequent FDA inspections, manufacturing validation, and finished-product release for Alferon, and whether commercial sales actually resumed.
- Track FDA discussions and the required scope, funding, and timing of further Ampligen studies; distinguish experimental findings from approved human uses.
- Assess cash burn against available cash and marketable securities, and the dilution and remaining capacity associated with the at-the-market offering.
- Verify final disposition and financial effects of the securities settlement and other disclosed legal proceedings.